Nodasic (Amisulpride)

Amisulpride, the active ingredient in Nodasic, is an atypical antipsychotic presented as an oral tablet for oral use. It is prescribed for the treatment of schizophrenia and related psychotic disorders in adults, and it also helps manage depressive symptoms associated with schizophrenia.

GNH USA supplies Nodasic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Amisulpride is used in the management of psychotic disorders by targeting dopaminergic pathways. - Schizophrenia: reduces positive and negative symptoms and improves overall functioning. - Psychotic disorders: controls acute psychotic episodes and stabilises chronic conditions. - Depressive symptoms associated with schizophrenia: alleviates mood disturbances linked to the primary illness.

Adverse reactions may occur with any antipsychotic therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Headache: transient cranial discomfort. - Insomnia: difficulty initiating or maintaining sleep. - Anxiety: heightened nervousness or tension. - Weight gain: modest increase in body weight. - Extrapyramidal symptoms (e.g., akathisia): mild motor restlessness.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: life‑threatening reaction with fever and rigidity. - Severe hypotension: marked drop in blood pressure. - QT‑prolongation: potential cardiac arrhythmia. - Agranulocytosis: dangerous reduction in white blood cells. - Severe extrapyramidal syndrome: persistent dystonia or parkinsonism. - Suicidal ideation: emergence of self‑harm thoughts.

Careful monitoring is required to minimise risks. - Monitor extrapyramidal symptoms: assess for movement disorders regularly. - Assess cardiac function: obtain baseline ECG and monitor QT interval. - Evaluate metabolic parameters: check weight, glucose, and lipid levels periodically. - Use caution in renal impairment: adjust dose if necessary. - Avoid abrupt discontinuation: taper under medical supervision. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Amisulpride may interact with several drug classes.

Major Interactions (Avoid): - Other dopamine antagonists: increased risk of severe extrapyramidal effects. - QT‑prolonging agents (e.g., certain antiarrhythmics): heightened arrhythmia risk. - Strong CYP2D6 inhibitors (e.g., fluoxetine): elevated plasma concentrations of amisulpride.

Moderate Interactions (Monitor Closely): - Alcohol: may enhance central nervous system depression. - Anticholinergic drugs: can mask early signs of movement disorders. - Lithium: potential for increased neurotoxicity when combined.